• PN: B115599


45x Ab-conjugated beads (S4P11 - Human CA19-9 Ab-bead). PN: B115599A. One vial containing 100 µL of anti-human CA19-9 conjugated to AimPlex Bead S4P11.

25x Biotin-detection Ab (Human CA19-9 Biotin-dAb). PN B115599B. One vial containing 100 µL of biotinylated anti-human CA19-9.

Lyophilized Standard Mix - Human CA19-9. PN: B115599S. One vial containing lyophilized CA19-9.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human Human CA19-9. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 0.5 mUnit/mL

Quantitation range:

LLOQ: < 1 Unit/mL

ULOQ: > 250 Unit/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%


Sample volume: 15 µL/test


CA19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9 (or sialylated Lewis (a) antigen) is a tumor marker that is used primarily in the management of pancreatic cancer. CA 19-9 is an antigen defined by monoclonal antibody binding to CA 19-9, the tumor surface marker Sialyl-Lewis A. CA 19-9 was discovered in the serum of patients with colon cancer and pancreatic cancer in 1981. CA 19-9 can be elevated in many types of gastrointestinal cancer, such as colorectal cancer, esophageal cancer and hepatocellular carcinoma. Apart from cancer, elevated levels may also occur in pancreatitis, cirrhosis, and diseases of the bile ducts. It can be elevated in people with obstruction of the bile ducts.


1. Perkins, G.; Slater, E.; Sanders, G.; Prichard, J. (2003). "Serum tumor markers". American family physician 68 (6): 1075–1082. PMID 14524394.

2. Magnani, JL (15 June 2004). "The discovery, biology, and drug development of sialyl Lea and sialyl Lex.". Archives of Biochemistry and Biophysics 426 (2): 122– 31. doi:10.1016/j.abb.2004.04.008. PMID 15158662.

3. Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981). "Specific antigen in serum of patients with colon carcinoma". Science 212 (4490): 53–5. doi:10.1126/science.6163212. PMID 6163212.

4. Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J, Somerfield M, Hayes D, Bast R (2006). "ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer". J. Clin. Oncol. 24 (33): 5313–27. doi:10.1200/JCO.2006.08.2644. PMID 17060676.

5. Goonetilleke KS, Siriwardena AK (April 2007). "Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer". Eur J Surg Oncol 33 (3): 266–70. doi:10.1016/j.ejso.2006.10.004. PMID 17097848.